You are about to be redirected to a site intended for people with primary HLH or their caregivers.
You are being redirected to a third party website.
Sobi takes no responsibility for the content of this website.
Interferon gamma (IFNγ) is the only type II interferon, and plays an important role in cell communication during immune responses.1-5 During innate immune responses, IFNγ helps eliminate intracellular pathogens by activating macrophages and natural killer (NK) cells.1,3 During adaptive immune responses, IFNγ is responsible for both the differentiation and overproliferation of activated T cells.6,7
IFNγ can be produced by CD4+ T-helper type 1 (T1) cells, activated CD8+ T cells, NK cells, natural killer T (NKT) cells, B cells, and antigen-presenting cells (APCs).1,7
Preclinical data suggest that the cytokine IFNγ plays a central and upstream role in the pathogenesis of primary hemophagocytic lymphohistiocytosis (HLH). Massive overexpression of IFNγ leads directly to downstream hypercytokinemia and hyperinflammation.2,8,9
While downstream cytokines—including IL-10, IL-12, IL-18, anti-TNF, anti-M-CSF, and anti-GM-CSF—likely impact inflammatory symptoms, animal studies attempting to suppress such cytokines have not shown any positive impact.2
In healthy individuals, antigen-presenting cells are recognized by cytotoxic CD8+ T cells, which bind to them to release perforin and granzymes into the immunological synapse space. Perforin creates pores in the target cell's plasma membrane, allowing the cytotoxic granzymes to enter and initiate lysis. In primary HLH, genetic mutations prevent perforin pore formation needed for cell lysis.10-12
Click through to see how IFNγ drives the uncontrolled release of cytokines, which result in the rapidly progressive and life-threatening symptoms of untreated primary HLH.
IFNγ drives the uncontrolled release of cytokines, which result in the rapidly progressive and life-threatening symptoms of primary HLH.
Primary hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory condition that mostly affects children, but can also occur in adults and teenagers.9,14,16,17
Gamifant reduces the inflammatory symptoms of primary HLH by neutralizing IFNγ.8
Gamifant is given as an intravenous infusion twice per week until the patient no longer requires therapy for the treatment of HLH or until hematopoietic stem cell transplantation (HSCT) is performed.8
Download the Start Form now or contact Gamifant Patient Services at 833-597-6530.